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Abstract
Background: E-proteins are transcription factors important for the development of a variety of
cell types, including neural, muscle and lymphocytes of the immune system. E2A, the best
characterized E-protein family member in mammals, has been shown to have stage specific roles in
cell differentiation, lineage commitment, proliferation, and survival. However, due to the
complexity of E2A function, it is often difficult to separate these roles using conventional genetic
approaches. Here, we have developed a new genetic model for reversible control of E2A protein
activity at physiological levels. This system was created by inserting a tamoxifen-responsive region
of the estrogen receptor (ER) at the carboxyl end of the tcfe2a gene to generate E2AER fusion
proteins. We have characterized and analyzed the efficiency and kinetics of this inducible E2AER
system in the context of B cell development.
Results: B cell development has been shown previously to be blocked at an early stage in E2A
deficient animals. Our E2AER/ER mice demonstrated this predicted block in B cell development, and
E2AER DNA binding activity was not detected in the absence of ligand. In vitro studies verified rapid
induction of E2AER DNA binding activity upon tamoxifen treatment. While tamoxifen treatment
of E2AER/ER mice showed inefficient rescue of B cell development in live animals, direct exposure of
bone marrow cells to tamoxifen in an ex vivo culture was sufficient to rescue and support early B
cell development from the pre-proB cell stage.
Conclusion: The E2AER system provides inducible and reversible regulation of E2A function at the
protein level. Many previous studies have utilized over-expression systems to induce E2A function,
which are complicated by the toxicity often resulting from high levels of E2A. The E2AER model
instead restores E2A activity at an endogenous level and in addition, allows for tight regulation of
the timing of induction. These features make our E2AER ex vivo culture system attractive to study
both immediate and gradual downstream E2A-mediated events.
Background
E2A, encoded by the tcfe2a gene and a member of the E-
protein family, is a basic helix-loop-helix (HLH) tran-
scription factor critical for regulating gene expression in
several developmental systems [1]. Originally identified
as an immunoglobulin (Ig) enhancer binding factor, E2A
has since largely been studied for its roles during the
development of B and T lymphocytes [2,3]. E2A partici-
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pates in various aspects of lymphocyte development
including lineage commitment, initiation of lineage spe-
cific gene expression, rearrangement of B and T cell recep-
tor genes, and differentiation through multiple
developmental stages. In addition to roles in lineage com-
mitment and cell differentiation, E2A has also been
shown to regulate cell cycle, proliferation, and survival.
E-proteins, including E2A, HEB, and E2-2 in mammals,
function as dimers to bind DNA and regulate gene expres-
sion. E2A homodimers are the primary E-protein dimers
functioning in B cells, whereas E2A-HEB heterodimers are
the primary dimers functioning in T cells [4-6]. Recent
data suggests that E2-2 homodimers are critical for plas-
macytoid dendritic cell development [7,8]. E2A also
serves as an important dimerization partner for tissue spe-
cific HLH transcription factors outside of the lymphoid
system. For example, E2A forms dimers with NeuroD and
MyoD, key regulators of neuronal and skeletal muscle
development, respectively [9-11]. Since E2A is the com-
mon factor for multiple lineage specific HLH transcription
factor dimers, novel tools for targeting and manipulating
E2A function can benefit a range of developmental biol-
ogy research areas.
Here we have developed a new genetic model to examine
E2A function. We have established an inducible E2A
mouse model by inserting a tamoxifen-responsive region
of the estrogen receptor (ER) ligand binding domain at
the carboxyl end of tcfe2a, resulting in the production of
E2AER fusion proteins. The use of tamoxifen inducible ER
fusion proteins in mouse genetics has already been estab-
lished as a valuable tool, especially with the vast use of the
Cre recombinase-ER fusion protein for inducible gene
knockout in mice [12-15]. In addition, ER fusion with a
variety of transcription factors has also been successfully
employed for analysis of gene expression. For example,
MyoD-ER fusion proteins have been expressed by viral
transduction in mouse embryonic fibroblasts for in vitro
study of MyoD gene regulation [16] and in mouse fibrob-
lasts for analysis of MyoD activation in vivo post trans-
plantation of transduced cells into recipient animals [17].
However, we do not know how useful the ER system will
be in live animals when targeting an endogenous locus.
Our E2AER system now introduces an ER fusion with a
bHLH transcription factor into the mouse genome for
analysis of an endogenously expressed protein.
E2AER/+  and E2AER/ER  mice, along with E2AER protein
function, are analyzed here in the context of B cell devel-
opment. A block in B cell development at the pre-proB cell
stage, prior to B lineage commitment, has been character-
ized by previous E2A-deficient mouse models [18,19]. A
rescue in B cell development from E2AER/ER pre-proB cells
upon tamoxifen treatment would be a stringent test to ver-
ify inducible E2AER function.
In this study, we provide the initial characterization of the
E2AER system. E2AER protein activity was rapidly induced
upon tamoxifen treatment and reversibly regulated by
tamoxifen withdrawal. Even though we show effective
induction of E2AER DNA binding activity, tamoxifen
treatment of E2AER/ER mice did not efficiently restore B
cells in vivo. However, tamoxifen treatment was able to
rescue and support early B cell development from E2AER/
ER pre-proB cells in an ex vivo culture system. Use of E2AER
ex vivo culture systems may therefore be beneficial for the
study of gene regulation in B cells and other E2A-regulated
cell lineages.
Results
Generation of the E2AER allele
E2AER/+  and E2AER/ER  mice were generated by using a
knock-in strategy for tamoxifen-inducible E2A function.
The tamoxifen-responsive ligand binding domain of the
mouse ER [20] was inserted at the carboxyl end of tcfe2a
to produce the E2AER allele (Figure 1A, B). With this tar-
geting strategy, similar to that used for the E2AGFP strain
previously developed in our lab [21], both alternatively
spliced products of the tcfe2a gene, E12 and E47, are trans-
lated as ER fusion proteins. Initial characterization of the
E2AER allele indicated normal expression levels of E2A
mRNA in the presence of the ER insertion (Figure 1C).
Previous study of E2A knockout mice has demonstrated
stunted growth and a high lethality rate of homozygous
animals within the first few weeks after birth [18,19]. In
contrast, the E2AE47bm strain, expressing a dominant neg-
ative form of E47, was originally described as indistin-
guishable from wild-type litter mates in size and survival
[22]. However, this work was analyzing mice on a mixed
genetic background. Upon backcrossing to C57BL/6, the
E2AE47bm/E47bm mice became smaller in size and demon-
strated the high lethality rate like that shown with the
knockout animals (unpublished data). E2AER/ER animals
also exhibit stunted growth and reduced survival (see
Additional file 1). Fortunately, the lethality rate in our
experience has been less severe in litters from the E2AER
strain than that observed with our E2A knockout and
dominant negative strains. However, we do not know if
this slight increase in postnatal survival is due to the pres-
ence of the E2AER protein or because our E2AER strain is
currently on a mixed background.
The E2AER allele resembles an E2A-deficient allele in the 
absence of ligand
B cells develop from hematopoietic stem cells (HSC) in
the bone marrow through a series of developmental stages
[23]. The pre-proB cell stage is an intermediate stage asBMC Developmental Biology 2009, 9:51 http://www.biomedcentral.com/1471-213X/9/51
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lymphoid progenitors develop into committed proB cells.
Pre-proB cells can be characterized by the expression of
B220 and CD43 and the absence of CD19 expression. As
pre-proB cells transition to the proB cell stage, CD19
expression is induced and cells undergo commitment to
the B cell lineage. E2A is critical for this transition, as dem-
onstrated by the block in development at the pre-proB cell
stage in E2A-deficient animals [18,19,24]. Analysis of
E2AGFP mice displays the up-regulation of E2A protein lev-
els from the pre-proB to proB stage (see Additional file 2)
[21]. This increase in E2A expression is likely critical for
E2A's regulation of the B cell lineage gene expression pro-
file given the importance of E2A gene dosage. For exam-
ple, elimination of one copy of E2A has been shown to
greatly reduce the number of proB cells [4,18].
Investigation of B cell development in E2AER/ER  mice
revealed a block at the pre-proB cell stage, similar to that
seen in the E2A-mutant E2AE47bm/E47bm mice (Figure 2A)
[22]. Occasionally we have observed a small population
of CD19+ B cells in the bone marrow of E2AER/ER mice, but
these incidences of leaky B cell development did not
appear to produce a significant population of mature, Ig
expressing B cells (Figure 2B). Even though E2A has been
suggested to influence proliferation in developing B cells
[20,25-27], no significant difference in expansion at the
pre-proB cell stage was observed by BrdU analysis of
E2AER/ER and wild-type mice (see Additional file 3).
For analysis of E2AER protein expression and DNA bind-
ing activity, we chose to derive Abelson transformed preB
cells from E2AER/+ and E2AER/ER bone marrow [28]. E2AER
protein expression was verified by Western Blot analysis
of whole cell lysates from E2AER/+ and E2AER/ER Abelson
cells (Figure 3A). While E2AER protein levels appeared
similar to wild-type levels when comparing E2A+/+ and
Generation of the E2AER allele Figure 1
Generation of the E2AER allele. (A) Targeting strategy for the generation of E2AER/+ and E2AER/ER mice. The 3' region of the 
mouse tcfe2a gene was used for targeting. Gene direction, the E47, E12, and 3' exons (gray boxes), and inserted tamoxifen-
responsive estrogen receptor ligand binding domain (ER, black box) are shown. Regions mediating homologous recombination 
are denoted by dotted lines. The selection markers pgkneo and pgktk are located as shown. (B) Genotyping PCR of E2A+/+, 
E2AER/+, and E2AER/ER DNA using primers yz164, yz29, and bjE2Ar3 as shown in (A), that yield a 0.9 kb wild-type allele and 1.2 
kb mutant allele. (C) RT-PCR of cDNA acquired from E2A+/+, E2AER/+, and E2AER/ER thymus RNA. E2A and GAPDH (control) 
expression was detected by semi-quantitative PCR of 5-fold serial dilutions.
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B cell developmental block at the pre-proB cell stage in E2AER/ER mice Figure 2
B cell developmental block at the pre-proB cell stage in E2AER/ER mice. (A) Representative staining of bone marrow 
cells from E2A+/+, E2AER/+, E2AER/ER, E2AE47bm/+, and E2AE47bm/E47bm mice. Cells are pre-gated on 7AAD- lymphocytes and rela-
tive percentages are given in each plot. Cells from the CD43+B220+ gate are displayed in histograms analyzing CD19 expres-
sion. Pre-proB (CD19-) and proB (CD19+) cell percentages are shown. (B) Occasional CD19+ B cell population detected in 
E2AER/ER mice. Staining of bone marrow from E2AER/ER and E2A+/+ mice for B220, CD43, CD19, and IgM expression. All plots 
are pre-gated on 7AAD- lymphocytes. Histograms are pre-gated on B220+CD43+ cells as above and relative percentages are 
shown.
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Induction and reversible regulation of E2AER DNA binding activity Figure 3
Induction and reversible regulation of E2AER DNA binding activity. (A) Detection of E2AER protein. Whole cell 
lysates were collected from E2A+/+, E2A-/-, E2AER/+, E2AER/ER, and E2AGFP/GFP Abelson-transformed preB cell lines and analyzed 
by Western Blot for E2A protein expression using an anti-E2A antibody. E2A+/+, E2AER/+, and E2AER/ER Abelson cells were also 
cultured with tamoxifen prior to analysis, as indicated. E2A+/+, E2AGFP/GFP, and E2A-/- lines were used as positive and negative 
controls for E2A proteins. ERK2 was used as a loading control. (B and C) Analysis of E2AER DNA binding activity. E2AER/ER 
Abelson-transformed preB cells were cultured (B) without and with tamoxifen for 1, 6 and 10 hr and (C) with tamoxifen and 
upon tamoxifen withdrawal for 1 and 6 hr. Nuclear extracts were analyzed by gel shift for E2A DNA-binding using a μE5 
probe. Anti-E2A antibody was used to demonstrate specificity (Ab). E2A-DNA complexes (arrow) and antibody-shifted com-
plexes (arrow head) are indicated. *Non-specific band.
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E2AER/ER  cells, analysis of E2AER/+  cells suggested that
E2AER protein expression may be lower than wild-type.
Protein analysis of tamoxifen treated cells displayed simi-
lar results, indicating that the relative E2AER protein lev-
els are not affected by the presence or absence of
tamoxifen. Nuclear extracts from E2AER/ER Abelson cells
were then used to conduct electrophoretic gel shift analy-
sis of E2AER binding to an E2A binding sequence, μE5. In
the absence of tamoxifen treatment, no DNA binding
activity was observed from the E2AER protein (Figure 3B).
Together, the block in B cell development and lack of
E2AER DNA binding activity suggest that the E2AER mouse
model functions as an E2A-deficient system in the absence
of ligand.
Rapid activation and reversible regulation of E2AER 
activity
Tamoxifen treatment of E2AER/ER Abelson cells resulted in
rapid E2AER DNA binding activity within 1 hr of treat-
ment (Figure 3B). The specificity of the protein binding to
the μE5 probe was verified by using an anti-E2A antibody
that effectively super-shifted the protein/DNA complex.
The effect of tamoxifen withdrawal was then tested by
washing tamoxifen-treated cells and growing them in the
absence of tamoxifen for 1 and 6 hr time points. Loss of
E2AER DNA binding activity was seen within 6 hrs of
tamoxifen withdrawal (Figure 3C), indicating relatively
fast reversibility of E2A function. These results demon-
strate that the E2AER model can be used not only as an
inducible model, but this system may also be valuable for
providing a tightly regulated window of E2A activity.
Induction of E2AER activity supports early B cell 
development ex vivo
We first tested for a functional outcome of E2A induction
by in vivo tamoxifen treatment of E2AER/ER mice followed
by analysis of B cell populations in the bone marrow and
spleen. All in vivo treatment efforts, including intraperito-
neal injection and treatment in drinking water, unfortu-
nately resulted in low efficiency rescue of B cell
development. The emergence of B cells in tamoxifen-
treated animals was rarely great enough to determine if
the resulting B cells were generated in response to the
tamoxifen treatment or were simply the incidence of leaky
B cell development described above. The most significant
recovery of B cells observed from in vivo treatment, which
resulted from a 27 day tamoxifen treatment, was still con-
siderably less than the B cell population in control mice
(Figure 4A, B). However, the presence of Ig μ heavy chain
(IgM) positive B cells in the spleen does suggest that a low
level of tamoxifen-dependent B cell development
occurred in vivo.
In contrast to in vivo tamoxifen treatment, treatment in an
ex vivo B cell culture system effectively rescued the devel-
opment of CD19+ B cells. Sorted E2AER/ER pre-proB cells
were cultured in hormone-free media on an S17 stromal
layer in the presence of IL-7, with or without tamoxifen.
Control DMSO treated E2AER/ER pre-proB cells failed to
develop efficiently into CD19+ B cells over the course of 5
days, whereas tamoxifen treated E2AER/ER pre-proB cells
effectively gave rise to CD19+ B cells (Figure 5A). Interest-
ingly, the kinetics of B cell development from tamoxifen
treated E2AER/ER pre-proB cells appeared delayed com-
pared to that of control cells. In addition to using CD19
expression to validate the rescue of B cell development, we
analyzed Pax5 expression throughout the 5 day culture.
Pax5, initiated downstream of E2A expression, is a tran-
scription factor critical for B cell lineage commitment
[29]. Consistent with CD19 expression, induction of Pax5
expression was observed in tamoxifen treated E2AER/ER
pre-proB cells, also appearing delayed compared to con-
trol cultures (Figure 5B).
Another key event during early B cell development, down-
stream of E2A function, is rearrangement of the Ig heavy
chain locus (IgH) [2,18,19]. We next used this culture sys-
tem to determine if induction of E2AER activity could also
support IgH V to DJ recombination. To amplify V to DJ
rearrangements, we chose primers recognizing members
of the VH1 gene family [30], which represent a large per-
centage of the total IgH V genes, and primers recognizing
the JH4 gene segment. Rearrangements were analyzed in
Day 8 cultured samples because we did not observe con-
sistent V to DJ PCR signals until this point in the time
course analysis. Wild-type mice were used as positive con-
trols for detecting recombination events, and mice defi-
cient in the recombination activating gene RAG1, required
for V(D)J recombination, were used as negative controls.
Analysis of Day 8 cultures demonstrated a clear V to DJ
rearrangement product from tamoxifen treated E2AER/ER
cells (Figure 6). V to DJ rearrangement was further verified
by sequencing analysis (see Additional file 4). The faint
product detected from DMSO control treated E2AER/ER
cells was accompanied by a small "leaky" CD19+ popula-
tion generated at this relatively late time point in the cul-
ture system (see Additional file 5). However, only one
unique rearrangement product was identified out of all of
the colonies sequenced for this sample. In addition to
providing functional proof of induced E2A activity, the
detection of IgH recombination, along with the induction
of CD19 and Pax5 expression described above, suggests
that restored E2A function can rescue B cell development
from the pre-proB cell stage.
Discussion
The E2AER system provides an improved method for ana-
lyzing E2A function. Previous analysis using over-expres-
sion of E2AER fusion proteins by retroviral transduction
has already demonstrated the value of inducible E2ABMC Developmental Biology 2009, 9:51 http://www.biomedcentral.com/1471-213X/9/51
Page 7 of 13
(page number not for citation purposes)
Inefficient rescue of B cell development upon in vivo tamoxifen treatment of E2AER/ER mice Figure 4
Inefficient rescue of B cell development upon in vivo tamoxifen treatment of E2AER/ER mice. (A) Two month old 
E2AER/+ and E2AER/ER control mice were treated with tamoxifen in their drinking water for 27 days. Indicated tissues were 
stained as shown. All plots are pre-gated on 7AAD- lymphocytes. Histograms are pre-gated on B220+CD43+ cells as shown. 
Relative percentages are displayed. (B) Representative spleen staining from age-matched non-treated E2AER/+ and E2AER/ER 
mice.
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Tamoxifen treatment restores B cell development from E2AER/ER pre-proB cells Figure 5
Tamoxifen treatment restores B cell development from E2AER/ER pre-proB cells. Sorted E2AER/+ and E2AER/ER pre-
proB cells were plated in hormone-free media on S17 stromal cells on Day 0 in the presence of IL-7 with tamoxifen or DMSO 
(untreated control). (A) Cells are pre-gated on 7AAD-B220+ lymphocytes. Percents of CD19+ cells on Day 1, 3, and 5 are dis-
played. Data are representative of 4 independent experiments. (B) Expression of Pax5 was analyzed by quantitative RT-PCR 
from RNA collected from Day 1, 3, and 5 cultures shown in (A). Samples were normalized to the expression of GAPDH. 
Graphed results are means from triplicate runs (n = 3) with error bars representing standard error of the mean (SEM).
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activity [20,31-34]. However, toxicity is often a problem
with high levels of E2A in the cell [20,35], and viral trans-
duction is not ideal for all cell types. In addition, the
changes in gene expression detected upon over-expression
of E2A may not always be representative of endogenous
E2A function. Therefore, generation of the E2AER allele
provides an attractive system for studying gene regulation
and other E2A-regulated events in potentially any E2A-
expressing cell type at a more physiological level.
Here we demonstrate the rapid induction of E2AER DNA
binding activity upon tamoxifen treatment and its poten-
tial for reversible function upon tamoxifen withdrawal.
The ability to tightly control E2A activity allows for kinetic
analysis of downstream events. Analysis of B cell develop-
ment in our ex vivo culture system demonstrated a rescue
from the pre-proB cell stage, but suggested delayed kinet-
ics from E2AER/ER pre-proB cells compared to B cell devel-
opment from control pre-proB cells. This result suggests
that even though E2AER/ER and wild-type pre-proB cells are
phenotypically similar, E2AER/ER pre-proB cells may not
have equivalent developmental potential or may require
additional cellular changes prior to entering the B cell lin-
eage. It is possible that E2A-regulated events normally
occurring earlier in development, as suggested in hemat-
opoietic stem cell (HSC), lymphoid-primed multipotent
progenitor (LMPP), and common lymphoid progenitor
(CLP) stages [27,36,37], were occurring upon restored
E2A function in pre-proB cells and requiring these cells to
"catch up" with their wild-type counterparts prior to pro-
gressing to the next stage. Alternatively, the developing
tamoxifen-treated E2AER/ER B cells may not have expanded
as rapidly as wild-type cells upon commitment to the B
cell lineage. Our Western Blot analysis of E2A proteins in
E2AER/+  Abelson cells (Figure 3A) suggested that the
E2AER protein level may also have been contributing to
the delayed kinetics. In this sample, the E2AER band
appeared less intense than the wild-type E2A band. How-
ever, it is not possible to determine from this analysis if
the lower intensity was a result of reduced protein levels
or variation in antibody affinity for the E2AER versus
wild-type E2A protein. In addition, there was not a strik-
ing difference between the E2AER and wild-type protein
levels when comparing the E2A+/+ and E2AER/ER samples.
Further investigation of tamoxifen treated E2AER/ER pre-
proB cells will be necessary to understand why the delayed
detection of CD19+ B cells was observed.
Our ex vivo culture data clearly indicated a rescue of early
B cell development to the proB cell stage. However, we
have so far been unable to determine if tamoxifen treat-
ment can rescue E2AER/ER B cells through the subsequent
preB cell stage, when E2A is known to be critical for Ig
kappa light chain (Igk) recombination [38]. We were una-
ble to test for induction of Igk recombination or surface
IgM expression by using our ex vivo culture system because
this system primarily supports development at a stage
prior to these events (see Additional file 5 and data not
shown). The presence of the small, but increased, popula-
tion of E2AER/ER IgM+ B cells in the in vivo treatment exper-
iment (Figure 4A) is the only current evidence suggesting
tamoxifen-induced E2AER activity may be able to rescue B
cell development to maturity. Additional B cell culture
systems would be necessary to determine if tamoxifen
treatment can rescue later stages of E2AER/ER B cell devel-
opment.
While in vivo tamoxifen treatment was not efficient for
restoring B cell development, in vivo treatment may still be
useful for analysis of E2A function in other cell lineages.
We suggest two reasons for ineffective rescue of in vivo B
cell development. First, progression through several stages
of lymphocyte development is known to be dependent on
proper E-protein dosage [4,6,18,26,39,40], and it is possi-
ble that the required E2A threshold is not maintained dur-
ing our in vivo treatment for rescue of B cell development.
For example, as mentioned above, we do not know if
E2AER/ER cells can sufficiently progress through the preB
cell stage of development. Second, E2A has been sug-
gested to be important for B cell survival [41]. Therefore,
it is conceivable that even if B cells are rescued by
tamoxifen treatment, they may be lost if E2AER activity is
not maintained throughout the treatment.
IgH recombination detected upon culture of tamoxifen  treated E2AER/ER pre-proB cells Figure 6
IgH recombination detected upon culture of 
tamoxifen treated E2AER/ER pre-proB cells. DNA was 
analyzed for IgH V to DJ rearrangements from Day 8 cul-
tured wild-type (WT), Rag1-/- (Rag) and E2AER/ER (ER) pre-
proB cells using VH1 and JH4 primers. Cells were cultured in 
hormone-free media on S17 stromal cells with IL-7 and 
tamoxifen (T) or DMSO (D). V-DJ rearrangement products 
using VH1 family gene segments and JH4 are shown. WT and 
Rag were used as positive and negative controls, respectively. 
No products were detected when using dH2O as an addi-
tional negative control (data not shown). CD14 was used to 
demonstrate DNA loading. This result is representative of 4 
independent nested PCR reactions.
CD14
VH1-DHJH4
0.5kb
1kb
WT Rag ER
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The E2AER system may instead be more valuable for in vivo
study of T cell development, or other lineages expressing
multiple E-protein family members. Since E-proteins
demonstrate many redundant functions, T cell develop-
ment is not completely blocked in E2A-deficient mice due
to the presence of HEB [4,6,42,43]. Because T cells are
fully developed in E2A-deficient mice, in vivo tamoxifen
treatment of E2AER/ER mice may be more valuable for the
study of E2A function during T cell development.
There are many additional applications for the E2AER sys-
tem. In addition to advantages in speed, expression level,
and reversibility, this inducible system may allow analysis
of E2A function in specific cell stages that have been diffi-
cult to analyze in previous E2A-deficient models.
Tamoxifen treatment of E2AER/ER cells may be valuable by
allowing progression to developmental stages that are
absent in E2A-deficient animals or affected due to the lack
of E2A at earlier developmental stages. E2AER/ER mice also
provide a useful tool for studying changes in E2A function
with age or for analyzing E-protein function in combina-
tion with other genetic models. Given the rapid induction
of E2AER DNA binding activity upon in vitro tamoxifen
treatment, we believe that the use of E2AER ex vivo culture
systems may be most valuable, especially for identifying
new E2A targets and studying the kinetics of E2A gene reg-
ulation.
Conclusion
We have established a new genetic model by generating
the E2AER allele. This model allows for inducible function
of E2A, a transcription factor displaying an extensive
range of functions across multiple developmental pro-
grams. E2AER activity is rapidly induced at the protein
level upon tamoxifen treatment and is reversible upon
tamoxifen withdrawal. Tamoxifen treatment of E2AER/ER
mice was, however, unable to efficiently restore wild-type
levels of B cells. The functionality of E2AER was instead
successfully verified by ex vivo tamoxifen treatment of
E2AER/ER B cell progenitors. In this ex vivo culture system,
induced E2AER protein function was able to rescue and
support early B cell development. Thus, the E2AER model
provides an attractive system to regulate and study E2A
protein function, especially under ex vivo conditions
where cells can gain sustained access to high levels of
tamoxifen.
Methods
Mice
E2AE47bm mice have been described previously [22]. Gen-
eration of the E2AER allele is described below. All research
with mice was performed in accordance with relevant
guidelines, and protocols were approved by the Duke
University Animal Care and Use Committee.
Generation of the E2AER allele
The gene targeting strategy used was a modification of the
strategy for generation of the E2AGFP  strain [21]. The
tamoxifen-responsive region of the mouse estrogen recep-
tor ligand binding domain containing the G525R muta-
tion [44] was PCR amplified from the MigR1-E47R vector
[20] using the primers ERfpA: 5'-CGGATCCACGAAAT-
GAAATGGGTGC-3' and ERrpA: 5'-CCGGCCGCTAGAAT-
TCGATCGTGTTGGGGAAGCCCTC-3' to introduce a 5'
BamHI site and 3' EcoRI and EagI sites for subsequent
cloning steps. The ER fragment was inserted, replacing
EGFP, at the BamHI position in frame with E2A. The tar-
geting construct also contained a positive selection
marker, PGKNeo cassette, and a negative selection
marker, PGK driven thymidine kinase (TK) cassette.
Mouse ES cells used were derived from a 129/sv strain
obtained from Phillippe Soriano's lab in 1995 and then
maintained in our own lab. E2AER/+ and E2AER/ER mice
were maintained on a C57BL6 and 129/sv mixed back-
ground. Three primers were used for detection of wild-
type and mutant alleles, yz164: 5'-AAGAACGAGGCCT-
TCCGTGTC-3', yz29: 5'-TCGCAGCGCATCGCCTTCTA-3',
and bjE2Ar3: 5'-CAAGAGACTAGGATGCCACTG-3'.
RT-PCR
RNA extraction, DNase I treatment and reverse transcrip-
tion have been described previously [41]. Quantitative
real-time PCR analysis for Pax5 expression was performed
using a Roche LightCycler and Fast-Start DNA master
SYBR green kit I (Roche) as per manufacturer's instruc-
tions. The following primers were used, E2A: f1 5'-
CCAGTCTCAGAGAATGGCAC-3' and r1 5'-CCTTCGCTG-
TATGTCCGGCTAG-3'; Pax5 and GAPDH primers [41].
Cell staining and flow-cytometry
For sorting, bone marrow was harvested and pooled from
2-3 mice per genotype. Cells positive for lineage markers
Mac-1, Gr-1, Ter-119, and CD3 were depleted with Dynal
Dynabeads (Invitrogen) according to manufacturer's
instructions. Dead cells stained with 7-aminoactinomycin
D (7AAD, Molecular Probes) were excluded. Pre-proB
cells were further distinguished as B220+CD43+CD19-.
FACS analysis was done with a FACSCalibur (BD Bio-
sciences) or FACSVantage SE with DiVa option (BD Bio-
sciences) and FlowJo software (Tree Star). FACSVantage
SE with DiVa option was used for cell sorting.
Tamoxifen preparation for in vitro culture treatment
Tamoxifen (Sigma) was prepared as a 1 mM stock
(1000×) dissolved in cell culture grade dimethyl sulfoxide
(DMSO) and stored at -20°C.
Abelson transformed preB cells
The E2AER/ER Abelson preB cell line was derived by Abel-
son Murine Leukemia Virus transformation of bone mar-BMC Developmental Biology 2009, 9:51 http://www.biomedcentral.com/1471-213X/9/51
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row cells from an E2AER/ER mouse. Briefly, whole bone
marrow was plated on an S17 stromal layer in the pres-
ence of 1 uM tamoxifen and 10 ng/mL IL-7 in 5% FBS
RMPI media. This culture was performed prior to trans-
duction to ensure cells were proliferating and were at the
optimal target stage for Abelson transformation. Once an
expanding B cell population was observed, cells were
infected with Abelson virus in the presence of 4 ug/mL
polybrene. Abelson transformed cells were then removed
from the stromal layer, and tamoxifen and IL-7 were with-
drawn. The established E2AER/ER Abelson preB cell line
was maintained in 10% FBS RPMI media (also containing
100 units/ml penicillin, 100 ug/mL streptomycin and 55
uM 2-mercaptoethanol) prior to experimental analysis.
Additional Abelson lines were established as described
previously [32].
Western Blot
Abelson preB cell lines were cultured without tamoxifen
or with 1 uM tamoxifen for 24 hr prior to analysis. Cells
were lysed in RIPA lysis buffer (1% Triton, 0.5% sodium
deoxycholic acid, 0.1% SDS, 25 mM Tris-Cl pH 7.6, 150
mM NaCl, 5 mM EDTA) with protease inhibitors. Whole
cell lysates were resolved by SDS-PAGE and blotted with
anti-E2A (G127-32, BD Biosciences, 554077) and anti-
ERK2 (C-14, Santa Cruz Biotechnology, sc-154) antibod-
ies.
Electrophoretic mobility shift assay
E2AER/ER Abelson preB cells were cultured with or without
1 uM tamoxifen as indicated. For withdrawal analysis,
tamoxifen-treated cells were washed and re-plated in the
absence of tamoxifen for the indicated times. Nuclear
extracts were incubated with a 32P-labeled μE5 oligonucle-
otide probe, with or without Yae anti-E2A monoclonal
antibody (Santa Cruz Biotechnology, sc-416), and
resolved on a 5% polyacrylamide gel. Gels were dried and
exposed to a phosphor screen for phosphorimager analy-
sis (Amersham Biosciences). Oligos used for μE5 probe:
5'-TCGAAGAACACCTGCAGCAGCT-3' and 5'-TAGAGCT-
GCTGCAGGTGTTCTT-3'.
In vivo tamoxifen treatment
Mice were treated with tamoxifen in the drinking water for
27 days. A 68 mg/mL tamoxifen in ethanol stock was used
to bring the concentration in drinking water to approxi-
mately 26 ug/mL, resulting in 0.04% ethanol in water. A
fresh bottle of tamoxifen water was given every 5 days.
Ex vivo pre-proB culture system
Sorted pre-proB cells were plated on an S17 stromal layer
in 24-well plates at approximately 1.5 × 104 cells per well
and cultured with 5% FBS RPMI hormone-free media con-
taining 10 ng/mL IL-7. Hormone free media consisted of
phenol-red free RPMI 1640 supplemented with 5% char-
coal/dextran treated FBS (Hyclone), 100 units/mL penicil-
lin, 100 ug/mL streptomycin, and 55 uM 2-
mercaptoethanol. Treated wells contained 1 uM
tamoxifen and untreated controls were given DMSO
alone (0.1%). Cells received fresh media, cytokine, and
tamoxifen or DMSO every other day. Cells were harvested
at time points indicated, and samples were split in half for
FACS analysis and RNA or DNA extraction.
IgH rearrangement analysis
Sorted pre-proB cells were ex vivo cultured as described
above. DNA was extracted from Day 8 cultures and then
analyzed for IgH V to DJ rearrangements using VH1 gene
family and JH4 specific primers. A nested PCR strategy was
used to amplify rearrangements involving VH1 family
gene segments. The following primers were used for
Round 1: VH1 ext 5'-AGRTYCAGCTGCARCAGTCT-3' [30]
and JH4 YZB6 5'-TCCCTCAAATGAGCCTCCAAAGTCC-3'
[45] and for Round 2: VH1 int 5'-GARGATRTCCTGYAAG-
GCTTC -3' [30] and JH4 YZB5 5'-CCTGAGGAGACGGT-
GACTGAGGTTCCTTG-3'[46]. CD14 primers were used to
demonstrate the presence of DNA in all samples [41].
VH1-DHJH4 PCR products were cloned into a pCR4 TOPO
vector (Invitrogen) and sequenced (Direct Sequencing
from Colonies Service, Eton Bioscience, Inc). Rearrange-
ment product sequences were analyzed by SoDA [47].
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